Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities.

Trabzonlu L, Kulac I, Zheng Q, Hicks JL, Haffner MC, Nelson WG, Sfanos KS, Ertunc O, Lotan TL, Heaphy CM, Meeker AK, Yegnasubramanian S, De Marzo AM.

Cold Spring Harb Perspect Med. 2018 Aug 6. pii: a030403. doi: 10.1101/cshperspect.a030403. [Epub ahead of print]

PMID:
30082453
2.

Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.

Yegnasubramanian S, De Marzo AM, Nelson WG.

Cold Spring Harb Perspect Med. 2018 Jun 29. pii: a030445. doi: 10.1101/cshperspect.a030445. [Epub ahead of print]

PMID:
29959132
3.

Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate.

Markowski MC, Hubbard GK, Hicks JL, Zheng Q, King A, Esopi D, Rege A, Yegnasubramanian S, Bieberich CJ, De Marzo AM.

Prostate. 2018 May 30. doi: 10.1002/pros.23657. [Epub ahead of print]

PMID:
29851094
4.

ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.

Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, De Marzo AM, Lotan TL.

Prostate. 2018 Sep;78(12):896-904. doi: 10.1002/pros.23646. Epub 2018 May 15.

PMID:
29761525
5.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2018 Apr 16. pii: S0302-2838(18)30246-X. doi: 10.1016/j.eururo.2018.03.028. [Epub ahead of print] Review.

PMID:
29673712
6.

The structure of the nucleus in normal and neoplastic prostate cells: untangling the role of type 2 DNA topoisomerases.

Nelson WG, Haffner MC, Yegnasubramanian S.

Am J Clin Exp Urol. 2018 Apr 1;6(2):107-113. eCollection 2018. Review.

7.

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.

Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.

PMID:
29577933
8.

The inflammatory microenvironment and microbiome in prostate cancer development.

Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM.

Nat Rev Urol. 2018 Jan;15(1):11-24. doi: 10.1038/nrurol.2017.167. Epub 2017 Oct 31. Review.

PMID:
29089606
9.

MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM.

J Pathol. 2018 Jan;244(1):11-24. doi: 10.1002/path.4980. Epub 2017 Nov 14.

10.

Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer.

Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW, Sfanos KS.

J Urol. 2018 Jan;199(1):161-171. doi: 10.1016/j.juro.2017.08.001. Epub 2017 Aug 7.

11.

AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination.

Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, Schaeffer EM, Lotan TL, Isaacs WB, Netto GJ, De Marzo AM, Nelson WG, An SS, Yegnasubramanian S.

Nat Commun. 2017 Jul 26;8(1):142. doi: 10.1038/s41467-017-00084-8.

12.

A Novel Functional Splice Variant of AKT3 Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers.

Guo T, Sakai A, Afsari B, Considine M, Danilova L, Favorov AV, Yegnasubramanian S, Kelley DZ, Flam E, Ha PK, Khan Z, Wheelan SJ, Gutkind JS, Fertig EJ, Gaykalova DA, Califano J.

Cancer Res. 2017 Oct 1;77(19):5248-5258. doi: 10.1158/0008-5472.CAN-16-3106. Epub 2017 Jul 21.

PMID:
28733453
13.

Inflammation, Microbiota, and Prostate Cancer.

Puhr M, De Marzo A, Isaacs W, Lucia MS, Sfanos K, Yegnasubramanian S, Culig Z.

Eur Urol Focus. 2016 Oct;2(4):374-382. doi: 10.1016/j.euf.2016.08.010. Epub 2016 Aug 28. Review.

PMID:
28723469
14.

Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations.

Mattox AK, Wang Y, Springer S, Cohen JD, Yegnasubramanian S, Nelson WG, Kinzler KW, Vogelstein B, Papadopoulos N.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):4733-4738. doi: 10.1073/pnas.1701382114. Epub 2017 Apr 17.

15.

c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.

Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG.

EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.

16.

Genetic landscape of extreme responders with anaplastic oligodendroglioma.

Holdhoff M, Cairncross GJ, Kollmeyer TM, Zhang M, Zhang P, Mehta MP, Werner-Wasik M, Souhami L, Bahary JP, Kwok Y, Hartford AC, Chakravarti A, Yegnasubramanian S, Vogelstein B, Papadopoulos N, Kinzler K, Jenkins RB, Bettegowda C.

Oncotarget. 2017 May 30;8(22):35523-35531. doi: 10.18632/oncotarget.16773.

17.

Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.

Ajiboye AS, Esopi D, Yegnasubramanian S, Denmeade SR.

Prostate. 2017 Jun;77(8):829-837. doi: 10.1002/pros.23323. Epub 2017 Feb 22.

18.

Prostate cancer epigenetics and its clinical implications.

Yegnasubramanian S.

Asian J Androl. 2016 Jul-Aug;18(4):549-58. doi: 10.4103/1008-682X.179859. Review.

19.

Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors.

Anders NM, Liu J, Wanjiku T, Giovinazzo H, Zhou J, Vaghasia A, Nelson WG, Yegnasubramanian S, Rudek MA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jun 1;1022:38-45. doi: 10.1016/j.jchromb.2016.03.029. Epub 2016 Mar 21.

20.

Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.

Gondek LP, Zheng G, Ghiaur G, DeZern AE, Matsui W, Yegnasubramanian S, Lin MT, Levis M, Eshleman JR, Varadhan R, Tucker N, Jones R, Gocke CD.

Leukemia. 2016 Sep;30(9):1916-1920. doi: 10.1038/leu.2016.63. Epub 2016 Mar 15. No abstract available.

21.

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Hedayati M, Haffner MC, Coulter JB, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Razavi N, Dalrymple S, Isaacs JT, Santos A, Hales R, Nelson WG, Yegnasubramanian S, DeWeese TL.

Clin Cancer Res. 2016 Jul 1;22(13):3310-3319. doi: 10.1158/1078-0432.CCR-15-1147. Epub 2016 Feb 1.

22.

Premalignancy in Prostate Cancer: Rethinking What we Know.

De Marzo AM, Haffner MC, Lotan TL, Yegnasubramanian S, Nelson WG.

Cancer Prev Res (Phila). 2016 Aug;9(8):648-56. doi: 10.1158/1940-6207.CAPR-15-0431. Epub 2016 Jan 26. Review.

23.

Global 5-Hydroxymethylcytosine Levels Are Profoundly Reduced in Multiple Genitourinary Malignancies.

Munari E, Chaux A, Vaghasia AM, Taheri D, Karram S, Bezerra SM, Gonzalez Roibon N, Nelson WG, Yegnasubramanian S, Netto GJ, Haffner MC.

PLoS One. 2016 Jan 19;11(1):e0146302. doi: 10.1371/journal.pone.0146302. eCollection 2016.

24.

Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.

Hubbard GK, Mutton LN, Khalili M, McMullin RP, Hicks JL, Bianchi-Frias D, Horn LA, Kulac I, Moubarek MS, Nelson PS, Yegnasubramanian S, De Marzo AM, Bieberich CJ.

Cancer Res. 2016 Jan 15;76(2):283-92. doi: 10.1158/0008-5472.CAN-14-3280. Epub 2015 Nov 10.

25.

GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress.

Mian OY, Khattab MH, Hedayati M, Coulter J, Abubaker-Sharif B, Schwaninger JM, Veeraswamy RK, Brooks JD, Hopkins L, Shinohara DB, Cornblatt B, Nelson WG, Yegnasubramanian S, DeWeese TL.

Prostate. 2016 Feb;76(2):199-206. doi: 10.1002/pros.23111. Epub 2015 Oct 8.

26.

Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.

Haffner MC, Weier C, Xu MM, Vaghasia A, Gürel B, Gümüşkaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, De Marzo AM.

J Pathol. 2016 Jan;238(1):31-41. doi: 10.1002/path.4628. Epub 2015 Oct 14.

27.

Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Hurley PJ, Hughes RM, Simons BW, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kimura Y, Jabbari J, Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, Netto GJ, Yegnasubramanian S, An SS, Schaeffer EM.

Cancer Res. 2015 Oct 15;75(20):4322-34. doi: 10.1158/0008-5472.CAN-15-0024. Epub 2015 Aug 20.

28.

Global DNA methylation changes and differential gene expression in Anaplasma phagocytophilum-infected human neutrophils.

Sinclair SH, Yegnasubramanian S, Dumler JS.

Clin Epigenetics. 2015 Jul 29;7:77. doi: 10.1186/s13148-015-0105-1. eCollection 2015.

29.

Should Gleason 6 be labeled as cancer?

Kulac I, Haffner MC, Yegnasubramanian S, Epstein JI, De Marzo AM.

Curr Opin Urol. 2015 May;25(3):238-45. doi: 10.1097/MOU.0000000000000165. Review.

30.

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR.

Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.

31.

Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation.

Singer BD, Mock JR, Aggarwal NR, Garibaldi BT, Sidhaye VK, Florez MA, Chau E, Gibbs KW, Mandke P, Tripathi A, Yegnasubramanian S, King LS, D'Alessio FR.

Am J Respir Cell Mol Biol. 2015 May;52(5):641-52. doi: 10.1165/rcmb.2014-0327OC.

32.

Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer.

Khor TO, Fuentes F, Shu L, Paredes-Gonzalez X, Yang AY, Liu Y, Smiraglia DJ, Yegnasubramanian S, Nelson WG, Kong AN.

Cancer Prev Res (Phila). 2014 Dec;7(12):1186-97. doi: 10.1158/1940-6207.CAPR-14-0127. Epub 2014 Sep 29.

33.

Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.

Tan HL, Haffner MC, Esopi DM, Vaghasia AM, Giannico GA, Ross HM, Ghosh S, Hicks JL, Zheng Q, Sangoi AR, Yegnasubramanian S, Osunkoya AO, De Marzo AM, Epstein JI, Lotan TL.

Mod Pathol. 2015 Mar;28(3):446-56. doi: 10.1038/modpathol.2014.115. Epub 2014 Sep 12.

34.

RNA-Seq of the nucleolus reveals abundant SNORD44-derived small RNAs.

Bai B, Yegnasubramanian S, Wheelan SJ, Laiho M.

PLoS One. 2014 Sep 9;9(9):e107519. doi: 10.1371/journal.pone.0107519. eCollection 2014.

35.

Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.

Lin MT, Mosier SL, Thiess M, Beierl KF, Debeljak M, Tseng LH, Chen G, Yegnasubramanian S, Ho H, Cope L, Wheelan SJ, Gocke CD, Eshleman JR.

Am J Clin Pathol. 2014 Jun;141(6):856-66. doi: 10.1309/AJCPMWGWGO34EGOD.

36.

Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer.

Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu VE, Sidransky D.

Epigenetics. 2014 Jul;9(7):1031-46. doi: 10.4161/epi.29025. Epub 2014 May 1.

37.

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.

Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Ali A, Srinivasan A, McLeod DG, Yegnasubramanian S, Srivastava S, Dobi A, Petrovics G.

Epigenetics. 2014 Jun;9(6):918-27. doi: 10.4161/epi.28710. Epub 2014 Apr 2.

38.

Diagnostic challenges of clonal heterogeneity in prostate cancer.

Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI, Carter HB.

J Clin Oncol. 2015 Mar 1;33(7):e38-40. doi: 10.1200/JCO.2013.50.3540. Epub 2014 Mar 17. No abstract available.

PMID:
24638011
39.

Time-Resolved Fluorescence Resonance Energy Transfer Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG Binding Domain Protein 2.

Wyhs N, Walker D, Giovinazzo H, Yegnasubramanian S, Nelson WG.

J Biomol Screen. 2014 Aug;19(7):1060-9. doi: 10.1177/1087057114526433. Epub 2014 Mar 7.

40.

Dietary chemoprevention of PhIP induced carcinogenesis in male Fischer 344 rats with tomato and broccoli.

Canene-Adams K, Sfanos KS, Liang CT, Yegnasubramanian S, Nelson WG, Brayton C, De Marzo AM.

PLoS One. 2013 Nov 27;8(11):e79842. doi: 10.1371/journal.pone.0079842. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/1ac6412e-619f-4575-8b63-f5e16bd3252b. PLoS One. 2014;9(1). doi:10.1371/annotation/3fd9703c-a6d9-4715-9c93-cf5279ea4fa6.

41.

Tracking the clonal origin of lethal prostate cancer.

Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S.

J Clin Invest. 2013 Nov;123(11):4918-22. doi: 10.1172/JCI70354. Epub 2013 Oct 25.

42.

Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network.

Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, Melamed J, Netto GJ, Trock BJ, De Marzo AM, Sfanos KS.

Prostate. 2014 Jan;74(1):61-9. doi: 10.1002/pros.22730. Epub 2013 Sep 21.

43.

The diet as a cause of human prostate cancer.

Nelson WG, Demarzo AM, Yegnasubramanian S.

Cancer Treat Res. 2014;159:51-68. doi: 10.1007/978-3-642-38007-5_4. Review.

44.

Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling.

Ghiaur G, Yegnasubramanian S, Perkins B, Gucwa JL, Gerber JM, Jones RJ.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16121-6. doi: 10.1073/pnas.1305937110. Epub 2013 Sep 16.

45.

Resistance emerges to second-generation antiandrogens in prostate cancer.

Nelson WG, Yegnasubramanian S.

Cancer Discov. 2013 Sep;3(9):971-4. doi: 10.1158/2159-8290.CD-13-0405.

46.

Explanatory chapter: next generation sequencing.

Yegnasubramanian S.

Methods Enzymol. 2013;529:201-8. doi: 10.1016/B978-0-12-418687-3.00016-1.

47.

Preparation of fragment libraries for next-generation sequencing on the applied biosystems SOLiD platform.

Yegnasubramanian S.

Methods Enzymol. 2013;529:185-200. doi: 10.1016/B978-0-12-418687-3.00015-X.

48.

Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.

Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):357-61. doi: 10.1038/pcan.2013.28. Epub 2013 Aug 20.

49.

Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene.

Alder JK, Parry EM, Yegnasubramanian S, Wagner CL, Lieblich LM, Auerbach R, Auerbach AD, Wheelan SJ, Armanios M.

Hum Mutat. 2013 Nov;34(11):1481-5. doi: 10.1002/humu.22397. Epub 2013 Sep 11.

50.

Tight correlation of 5-hydroxymethylcytosine and Polycomb marks in health and disease.

Haffner MC, Pellakuru LG, Ghosh S, Lotan TL, Nelson WG, De Marzo AM, Yegnasubramanian S.

Cell Cycle. 2013 Jun 15;12(12):1835-41. doi: 10.4161/cc.25010. Epub 2013 May 15.

Supplemental Content

Loading ...
Support Center